Sector: MedicalSeattle Genetics, Inc. (NASDAQ: SGEN)
Headlines
- Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75
Nov 16, 2009 09:00 AM | SGEN
- Seattle Genetics to Present at Upcoming Investor Conferences
Oct 27, 2009 04:05 PM | SGEN
- Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results
Oct 22, 2009 04:10 PM | SGEN
- RidgewaterEquity.com Free Fundamental Sector & Market Research on SGEN, PLUG, RIGL, PAET, RPRX and PLAB
Oct 22, 2009 06:31 AM | PAET, PLUG, RIGL, SGEN
- Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2009 Financial Results on October 22, 2009
Oct 15, 2009 09:00 AM | SGEN
- Seattle Genetics Names Head of Commercial and Announces Management Promotion
Oct 13, 2009 09:01 AM | SGEN
- Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Oct 05, 2009 08:04 AM | AMGN, ARRY, ONTY, SGEN, ZGEN
- Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial
Oct 05, 2009 07:01 AM | SGEN
- Seattle Genetics to Present at JMP Securities Healthcare Focus Conference
Sep 29, 2009 09:01 AM | SGEN
- ZymoGenetics Appoints Dennis M. Miller, Ph.D., Senior Vice President, Research and Preclinical Development
Sep 18, 2009 04:30 PM | AMGN, SGEN, ZGEN
- Seattle Genetics Announces Exercise of Over-Allotment Option
Aug 13, 2009 10:05 AM | SGEN
- Seattle Genetics Announces Pricing of Public Offering of Common Stock
Aug 11, 2009 05:49 PM | SGEN
- Seattle Genetics Announces Proposed Public Offering of Common Stock
Aug 10, 2009 04:08 PM | SGEN
- Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune
Aug 10, 2009 09:16 AM | SGEN
- StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)
Jul 27, 2009 06:51 AM | AMGN, ONXX, OSIP, PFE, SGEN
- Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
Jul 24, 2009 09:01 AM | SGEN
- Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results
Jul 23, 2009 04:26 PM | SGEN
- Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009
Jul 17, 2009 09:03 AM | SGEN
- Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma
Jun 18, 2009 09:10 AM | SGEN
- Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma
Jun 08, 2009 09:33 AM | SGEN
- Form 4 SEELEY BRUCE J. For: Oct 30 (10K)
Nov 02, 2009 07:53 PM
- Form 4 DOBMEIER ERIC For: Oct 29 (10K)
Nov 02, 2009 07:30 PM
- Form 4 SIEGALL CLAY B For: Sep 08 (10K)
Sep 09, 2009 08:58 PM
- Form 4 SIMPSON TODD E For: Aug 25 (10K)
Aug 26, 2009 08:40 PM
- Form 4 SIEGALL CLAY B For: Aug 25 (10K)
Aug 26, 2009 08:38 PM
- Form 4 ROSENBERG MORRIS For: Aug 25 (10K)
Aug 26, 2009 08:37 PM
- Form 4 Reynolds Thomas C For: Aug 25 (10K)
Aug 26, 2009 08:34 PM
- Form 4 HIMES VAUGHN B For: Aug 25 (10K)
Aug 26, 2009 08:32 PM
- Form 4 DOBMEIER ERIC For: Aug 25 (10K)
Aug 26, 2009 08:28 PM
- Form 4 SEATTLE GENETICS INC For: Aug 18 Filed by: AKKARAJU SRINIVAS (10K)
Aug 20, 2009 04:24 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
SGEN
|
Compare to S&P
|
| YTD |
4.81 %
|
-13.42 %
|
| 4 Weeks |
-7.04 %
|
-7.54 %
|
| 12 Weeks |
-21.33 %
|
-26.17 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 19.23 %
|
|
EPS Growth in Last Year: 22.22 %
|
|
Sales Growth in Last Quarter: 23.79 %
|
|
Sales Growth in Last Quarter: 44.15 %
|
|
